The initiation and progression of cancer, traditionally seen as a genetic disease, is now realized to involve epigenetic abnormalities along with genetic alterations. Recent advancements in the rapidly evolving field of cancer epigenetics have shown that disruption of various epigenetic mechanisms includes non-coding RNAs, such as microRNAs, DNA methylation, histone modifications, and nucleosome positioning are central to switching normal cells to malignant cells.
Thermo Fisher Scientific has developed powerful epigenetic research technologies spanning renewable antibody development, sample preparation, sequencing, quantitative PCR, & functional analysis assays to help unlock the mysteries of the cancer cell.
Renewable epigenetic antibodies
Epigenetic regulatory proteins are involved in a wide variety of chronic diseases, such as cancer, and are the target of an explosive new field of drug discovery. The ability to properly study most epigenetic changes, which determine which genes are “turned off and on,” are determined by the effectiveness of one critical tool—antibodies. Thermo Fisher Scientific has partnered with the Structural Genomics Consortium (SGC) to develop high-quality recombinant antibodies to read, write, and erase the epigenetic code.
Discover the noncoding RNAs that regulate cancer
MicroRNA & small RNA isolation
MicroRNA profiling & validation
Functional analysis (in vitro or in vivo)
Read, write, & erase the epigenetic code through dynamic protein-DNA complexes
Map proteins across the genome
Understand chromatin structure
Investigate enzymes & substrate modifications
Profile chromatin enzymes or substrates
For Research Use Only. Not for use in diagnostic procedures.